IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Harnessing Artificial Intelligence For Enhanced Pharmacovigilance

A Comprehensive Review

Author :- **ABHISHEK SINGH*, ABHAY CHAUHAN, ABHISHEK NISHAD, ABHISHEK SIDDHARTH ,**

KRISHNANAND PRAJAPATI

NIRMALA DEVI PHARMACY COLLEGE, NAYANSAND,GAURABADSHAHPUR, JAUNPUR

ABSTRACT :

The potential of artificial intelligence (AI) to automate data collection, analysis, and interpretation from multiple sources is the main topic of this paper, which examines the integration of AI into pharmacovigilance (PV) systems. In addition to discussing difficulties and moral issues including algorithmic prejudice and data privacy, it offers suggestions for further study and application in this important area.

Keywords: Pharmacovigilance, Artificial Intelligence, Adverse drug reactions.

INTRODUCTION:

The scientific field of pharmacovigilance keeps an eye on pharmaceuticals both before and after they are p ut on the market in order to identify, assess, and stop side effects, prescription errors, and drug interactions. It is essential for clinical practice, public health campaigns, and efficient medication regulation. It also improves drug safety, increases reporting rates, and lowers adverse responses.

Methods of pharmacovigilance have historically included case studies, literature reviews, and spontaneous reporting systems (SRS).

In order to identify safety signals, manufacturers, patients, or healthcare professionals can voluntarily submit reports of adverse drug reactions (ADRs) to databases such as VigiBase or FAERS. However, safety detection may be hampered by issues including underreporting, data duplication, and processing enormous numbers.

Machine learning, natural language processing, neural networks, computer vision, and robotics are examples of technologies that fall under the umbrella of artificial intelligence (AI). By analyzing data, identifying patterns, and making judgments with little assistance from humans, these technologies simulate human intelligence. They also make it possible to build and operate AI- capable robots.

Because of the shortcomings of conventional approaches, including manual data processing, underreporting of adverse drug reactions (ADRs), and delays in safety signal identification, artificial intelligence (AI) is required in pharmacovigilance. As evidenced in Morocco, where AI boosted spontaneous reports from 3.6 to 37.4 cases, AI can automate data processing, increase signal detection accuracy, and expedite ADR reporting.

The several uses of artificial intelligence (AI) in the pharmaceutical industry are covered in the article:

❖ In order to manage and avert possible problems, adverse event detection and reporting are essential:

The massive volume of data from sources such as social media, scientific literature, and electronic health records might make manually reporting Adverse Events (AEs) slow. The early identification and reporting of safety hazards is hampered by this data overload. Extracting adverse event information from several sources requires the integration of automated technologies such as Natural Language Processing (NLP). Real-time drug safety monitoring from social media platforms is made possible by NLP's assistance in identifying drug names and related side effects. An AI-enabled program called SPINEL has shown excellent accuracy in identifying known opioid-related adverse drug reactions. The study looks for possible adverse drug effects (ADEs) connected to particular opioid medications using keyword and trigger-phrase searches.

❖ The method of managing and detecting signals is the main topic of the text:

Pharmacovigilance's traditional signal detection techniques can be laborious and ineffective, missing signals and safety issues. The effectiveness and accuracy of detecting possible adverse drug reactions and new safety signals have been greatly increased by advanced techniques like artificial intelligence (AI) technology, such as machine learning and data mining. By analyzing both structured and unstructured data, these technologies are able to identify intricate patterns and connections sooner than traditional methods. Generative AI can enhance signal detection, data analysis, and risk assessment in addition to automating the preparation of case reports, identifying unfavorable events, and prioritizing safety signals. However, in order to evaluate and act upon these insights, human monitoring and confirmation are essential.

❖ In order to manage any hazards, risk assessment and mitigation are essential processes:

According to ClinChoice's research, 90% of pharmacovigilance efforts concentrate on post-market surveillance, which causes delays in resolving safety concerns and forecasting unfavorable outcomes because of intricate aspects.

Risk prediction models driven by AI are essential for evaluating and reducing drug safety risks. AI can find trends and indicators of possible safety issues by examining big datasets. These algorithms outperform conventional techniques by predicting patient- specific hazards with an accuracy of up to 85%. AstraZeneca has shown how AI-based models can revolutionize healthcare practices by incorporating them into clinical trials.

❖ The case processing procedure and the start of the trial are the main topics of the text:

Incomplete data, lengthy procedures, and delays in triaging are the main causes of manual case processing inefficiency. By automating the processing of individual case safety reports, AI can increase accuracy and efficiency. When adopting AI technology, for instance, the Pharmacovigilance Department of Indonesian vaccine makers reported a 219% boost in performance value. AI improves operational productivity and safety monitoring procedures by lowering human error, guaranteeing consistency, and freeing up resources for more difficult decision- making duties.

❖ The practice of keeping an eye on the market before it enters a particular market is known as post-market surveillance:

Traditional methods are insufficient for post-market medication safety monitoring because of the large volume of data from several sources. AI is essential to this process because it processes real-time data from multiple sources to spot new safety concerns and send out timely notifications. AI-driven solutions can improve patient safety and public health outcomes by analyzing large datasets, identifying adverse medication responses, and prioritizing alarms according to severity

.

❖ The employment of spontaneous reporting systems is the main topic of the text:

Pharmacovigilance relies heavily on spontaneous reporting systems, such as the FDA Adverse Event Reporting System (FAERS), which collect and analyze data on adverse medication reactions. AI techniques improve speed and accuracy by automating the processing of Individual Case Safety Reports, enabling prompt regulatory replies. A sociotechnical framework that encompasses technology, evaluation, people, workflows, and organizational policies is necessary because AI is not yet ready for full automation.

CASE STUDIES AND REAL-WORLD EXAMPLES

❖ The application of AI-based optimization strategies in social media platforms is covered in the paper:

A study by Roche et al. highlighted the possibility for better pharmacovigilance by using AI and machine learning to evaluate social media user behavior indicators and detect ADEs with a 75% accuracy rate.

❖ An overview of the medications used to treat COVID-19 is given in the text:

AI-based adaptive signal detection techniques were employed to find pulmonary Adverse Drug Events (pADEs) connected to hypertension drugs during the COVID- 19 pandemic. Significant differences across medicines were found in the study by Xu et al., which analyzed drug interactions and ADEs using sophisticated approaches like GPS, GLASSO clustering, and penalized regression.

Table 1 highlights the benefits of AI-enhanced solutions over traditional pharmacovigilance in terms of accuracy, data entry, and reporting quality. While traditional approaches encounter errors and inconsistencies, artificial intelligence (AI) automates data extraction, cross-checks, and provides real-time monitoring.

❖ The difficulties and constraints of many facets of life are covered in the work:

Securing high-quality, easily accessible data is a barrier for the use of AI in pharmacovigilance since biased and incomplete datasets can reduce the efficacy of machine learning models and make it more difficult to accurately identify adverse drug reactions (ADRs).

Figure 1: Applications of AI in Pharmacovigilance

The idea of algorithm bias and how it affects interpretability are covered throughout the text:

In pharmacovigilance, algorithmic bias in AI applications can produce skewed and sometimes dangerous results. The ability of AI models to be interpreted is essential for regulatory approval and trust, but many of them operate as "black boxes," making it challenging to comprehend how they make decisions, which hinders their use in pharmacovigilance.

Agencies are using artificial intelligence (AI) technologies to collect and track undesirable incident:

AI is being used to enhance ADR detection at the Uppsala Monitoring Centre (UMC), which has the largest database of Individual Case Safety Reports (ICSRs) in the world.



Figure 2: Challenges and Limitations in Pharmacovigilance.

❖ The application of AI in EudraVigilance is covered in the paper:

By using artificial intelligence (AI) for early safety signal identification, EudraVigilance helps the European Medicines Agency (EMA) prioritize high-risk cases, automate data processing, and uncover drug safety concerns from EU member states.

❖ One of the most important components of our research and development initiatives is the cooperation between academics and industry:

In order to improve post-market surveillance and forecast adverse medication reactions, the European Medicines Agency (EMA) is working with pharmaceutical companies and academic institutes to create artificial intelligence (AI) models.
The regulatory agency in charge of overseeing and approving medical items in China is the National Medical items Administration (NMPA).
To enhance acute drug resistance (ADR) monitoring, China's National Medical Products Administration (NMPA) is incorporating artificial intelligence (AI) into its pharmacovigilance system.

❖ AI-Powered Safety Monitoring:

In order to identify possible safety signals, the National Medical Practitioners Association (NMPA) analyzes clinical trial data, electronic health records, and adverse drug reaction (ADR) reports using artificial intelligence (AI) algorithms.

❖ CONCLUSION:

By effectively analyzing large datasets, detecting adverse responses early, and minimizing human error, AI improves pharmacovigilance. However, it also presents issues related to data quality, algorithm transparency, and regulatory compliance.

REFERENCE :

1. Sameena S, Shafi S, P.b D. Necessity, Importance, Future Aspects and Challenges of Pharmacovigilance. Asian J Pharm Res Dev. 2022;10(6):110-9.

2. Review on Concept of Pharmacovigilance. Int J Adv Res Sci Commun Technol. 2023;462-8.

3. Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety | IntechOpen

4. Sharma R, Nandave M, Kumar A. Introduction to Signal Detection in Pharmacovigilance. In: Nandave M, Kumar A, editors. Pharmacovigilance Essentials: Advances, Challenges and Global Perspectives, Singapore: Springer Nature; 2024, p. 333- 45.

5. Overview of Artificial Intelligence Technology | FINRA.org

6. Tanani DS, Serragui S, Hammi S, Moussa LA, Soulaymani A, Soulaymani R, et al. National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program. Pan Afr Med J. 2017;26(48).

7. Sorbello A, Haque SA, Hasan R, Jermyn R, Hussein A, Vega A, et al. Artificial Intelligence-Enabled

Software Prototype to Inform Opioid Pharmacovigilance from Electronic Health Records: Development and Usability Study. JMIR AI. 2023;2(1):e45000.

8. Chavhan AR, Uplenchwar PM. AI-Driven Signal Detection in Pharmacovigilance: Advancements, Challenges and Future Directions. Int J Pharm Pharm Res. 2024;30(5):99- 119.

9. Praveen J. Empowering Pharmacovigilance: Unleashing the Potential of Generative AI in Drug Safety Monitoring. J Innov Appl Pharm Sci JIAPS. 2023;24-32.

10. ClinChoice. 2022 Pharmacovigilance: Literature Monitoring Best Practices.

11. Data Science and Artificial Intelligence: Unlocking new science insights

12. Irham A, Basri MH. Processing of Individual Case Safety Reports in The Pharmacovigilance Department of Indonesian Vaccine Companies. J World Sci. 2023 May 27;2(5):711-25.

13. Salvo F, Micallef J, Lahouegue A, Chouchana L, Létinier L, Faillie JL, et al. Will the future of pharmacovigilance be more automated? Expert Opin Drug Saf. 2023;22(7):541- 8.

14. Ball R, Dal Pan G. "Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time? Drug Saf. 2022 May 1;45(5):429-38.

15. Roche V, Robert JP, Salam H. A holistic AI-based approach for pharmacovigilance optimization from patients behavior on social media. Artif Intell Med. 2023;144:102638.

16. Xu X, Kawakami J, Gedara NIM, Riviere J, Meyer E, Wyckoff GJ, et al. Data-driven methodology for discovery and response to pulmonary symptomology in hypertension through AI and machine learning: Application to COVID-19 related pharmacovigilance, medRxiv; 2021, p. 2021.06.07.21258497.

17. Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionising drug development: Exploring opportunities and challenges. Drug Dev Res. 2023;84(8):1652- 63.

18. Tran MH, Nguyen NQ, Pham HT. A New Hope in the Fight Against Antimicrobial Resistance with Artificial Intelligence. Infect Drug Resist. 2022;15:2685-8.

19. Babu KA, Ms S, As MD. Artificial Intelligence in Pharma. Int J Curr Res Physiol Pharmacol 2021.

20. Sourajyoti Goswami, Mohit Kumar Singh. Artificial Intelligence used in Pharmaceutical and Healthcare Industry: A Review. Int J Adv Res Sci Commun Technol. 2023;428-38.

21. Zheng Y, Rowell B, Chen Q, Kim JY, Kontar RA, Yang XJ, et al. Designing Human- Centered AI to Prevent Medication Dispensing Errors: Focus Group Study with Pharmacists. JMIR Form Res. 2023;7(1):e51921.

22. Uppsala Reports 20241022. Artificial intelligence in pharmacovigilance: Harnessing potential, navigating risks.

23. Research C for DE and. FDA Adverse Event Reporting System (FAERS) Electronic Submissions. FDA. 2024.

24. Artificial intelligence work plan to guide use of AI in medicines regulation | European Medicines Agency (EMA). 2023.

25. MHRA_Impact-of-AI-on-the-regulation-of-medical-products.pdf

26. Rossello J. Pharmacovigilance Analytics. 2023. Introduction to AI in Drug Safety Monitoring: Revolutionizing Pharmacovigilance.

27. Shamim MA, Shamim MA, Arora P, Dwivedi P. Artificial intelligence and big data for pharmacovigilance and patient safety. J Med Surg Public Health. 2024;3:100139.
28. Kang HS. AI and pharma: Transforming the paradigm, embracing the new era. Artif Intell Health. 2024;0(0):2973.
29.